{"product_id":"coryfin-gola-dolore-2-5-mg-ml","title":"CORYFIN THROAT PAIN 2.5 MG\/ML","description":"\u003cb\u003eName\u003c\/b\u003e\u003cbr\u003e CORYFIN THROAT PAIN 2.5 MG\/ML\u003cbr\u003e\u003cbr\u003e \u003cb\u003eActive ingredients\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eCORYFIN GOLA DOLORE 2.5 mg\/ml mouthwash\u003c\/i\u003e 1 ml of solution contains: flurbiprofen 2.5 mg \u003ci\u003eCORYFIN GOLA DOLORE 2.5 mg\/ml oral mucosa spray\u003c\/i\u003e 1 ml of solution contains: flurbiprofen 2.5 mg \u003cu\u003eExcipients with known effect\u003c\/u\u003e : methyl parahydroxybenzoate, propyl parahydroxybenzoate, macrogolglycerol hydroxystearate. For the full list of excipients, see section 6.1\u003cbr\u003e\u003cbr\u003e \u003cb\u003eTherapeutic indications\u003c\/b\u003e\u003cbr\u003e Symptomatic treatment of irritative-inflammatory conditions also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.\u003cbr\u003e\u003cbr\u003e \u003cb\u003eDosage\u003c\/b\u003e \u003cbr\u003eUndesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). \u003ci\u003eCORYFIN GOLA DOLORE 2.5 mg\/ml mouthwash\u003c\/i\u003e \u003cu\u003eDosage\u003c\/u\u003e The recommended dose is two or three rinses or gargles per day with 10 ml of mouthwash. \u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Rinse or keep in the mouth during gargling for up to 1 minute. Do not swallow. The mouthwash can be diluted in water. \u003ci\u003eCORYFIN GOLA DOLORE 2.5 mg\/ml oral mucosal spray\u003c\/i\u003e \u003cu\u003eDosage\u003c\/u\u003e The recommended dose is 2 sprays 3 times a day directed directly at the affected area. \u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Aim the dispenser and spray on the affected area. \u003ci\u003ePaediatric population\u003c\/i\u003e Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eElderly\u003c\/i\u003e : Currently available clinical data are limited; therefore, no recommendation on posology can be made. Elderly are at increased risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with hepatic impairment\u003c\/i\u003e : No dosage reduction is necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal impairment\u003c\/i\u003e : No dosage reduction is necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cbr\u003e \u003cbr\u003e\u003cb\u003eConservation\u003c\/b\u003e\u003cbr\u003e This medicinal product does not require any special storage conditions. For storage conditions after first opening, see section 6.3.\u003cbr\u003e\u003cbr\u003e \u003cb\u003ePregnancy and breastfeeding\u003c\/b\u003e \u003cbr\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or the embryo-foetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-foetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, flurbiprofen should not be administered unless clearly necessary. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: - Cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - Renal dysfunction, which may progress to renal failure with oligohydramnios; the mother and neonate, at the end of pregnancy, to: - Possible prolongation of bleeding time, an antiaggregant effect which may occur even at very low doses. - Inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, flurbiprofen is contraindicated during the third trimester of pregnancy. \u003cu\u003eBreastfeeding\u003c\/u\u003e Flurbiprofen is excreted in breast milk; however, the amount excreted is only a small fraction of the maternal dose and is unlikely to have any adverse effects on the breast-fed infant. Administration of flurbiprofen is not recommended in nursing mothers. \u003cu\u003eFertility\u003c\/u\u003e There is evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility by an effect on ovulation. This is reversible upon discontinuation of treatment.","brand":"SIT LABORATORIO FARMAC. SRL","offers":[{"title":"Default Title","offer_id":50957199737166,"sku":"041827027","price":8.24,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0845\/6214\/9710\/files\/TE004-H0009738.png?v=1768765130","url":"https:\/\/farmaspeed.it\/en-eu\/products\/coryfin-gola-dolore-2-5-mg-ml","provider":"Farmaspeed","version":"1.0","type":"link"}